About SR Bio-Tech

Small particles, great achievements. Through precise diagnosis and treatment, alleviate patient suffering and benefit all of humanity

Who we are

Shanghai Shengran Biotechnology Co.,Ltd(SR Bio-Tech). was founded in March 2018 by top-notch Ph.D. graduates from domestic and foreign leading universities, with a registered capital of 10.1 million RMB. The company's core team is composed of recipients of the National Outstanding Youth and Thousand Youth Talents awards, as well as renowned Ph.D. and master's degree holders from domestic and international prestigious universities. Situated in the core area of the Shanghai International Medical Park in Zhangjiang Science City,

 

 

Core Technology

SR Bio-Tech focuses on the preparation and capture of engineered extracellular vesicles (EVs), multi-omics detection, and data analysis of EV sources, as well as cell-targeted drug delivery.The company's core technologies include nucleic acid and protein detection kits for EVs derived from tumor cells, core products such as anti-tumor protein drugs, and monoclonal antibodies for new immunotherapy targets. The core vision is to provide optimal diagnosis and treatment solutions for cancer patients. Since its establishment, the company has collaborated with dozens of top-tier hospitals in China, playing a key role in more than ten national and provincial-level key science and technology innovation projects and basic research projects, with a total approved funding exceeding tens of millions.

Research Platform

SR Bio-Tech has established a workstation for the enrichment and characterization of EVs, an NGS sequencing and LC-MS mass spectrometry multi-omics experimental and data analysis platform, and a standardized nucleic acid amplification laboratory. These facilities provide solid platform support for the medical transformation of EVs.

 

Qualification

As a rapidly growing high-tech biotech company, SR Bio-Tech was recognized as a national-level high-tech enterprise in August 2019 and completed Series A financing in 2022. The company has accumulated more than 10 authorized invention patents, completed several Type I production filings for small extracellular vesicle (sEV) extraction systems with the National Medical Products Administration (NMPA), and has multiple gene detection kits in the application stage for Class III medical device registration.

 

Culture

"Innovation, pragmatism, and people-oriented" constitute the core culture of SR Bio-Tech. Their vision is to become a leader in the diagnosis and treatment of small extracellular vesicles. The motto is "Small particles, great achievements. Through precise diagnosis and treatment, alleviate patient suffering and benefit all of humanity."